# IMRX catalysts: Immuneering Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imrx/catalysts

> Immuneering Corp (IMRX) has 6 upcoming catalysts. The next is the atebimetinib topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IMRX?

Immuneering Corp (IMRX) has 6 upcoming catalysts. The next is the atebimetinib topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/imrx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001790340-26-000095, https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/companies/imrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Immuneering Corp |
| Ticker | IMRX (Nasdaq) |
| SEC CIK | 1790340 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/imrx |

## Cash runway

Cash $58.2M as of 2026-09-30; quarterly burn $16.8M; about 10.4 months of runway at that rate (XBRL company facts, accession 0001790340-26-000097).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [Atebimetinib trial start](https://sec-api.dev/pdufa/atebimetinib) | IMRX | with advanced or metastatic solid tumors | completed | "In September 2022, the FDA cleared our IND application for atebimetinib and, in November 2022, we commenced dosing in our Phase 1/2a clinical trial of atebimetinib for the potential treatment of patients with advanced or metastatic solid tumors." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000135/imrx-20250930.htm)) |
| Mar 2024 | [Envometinib trial start](https://sec-api.dev/pdufa/envometinib) | IMRX | with advanced solid tumors harboring RAF or RAS mutations | completed | "In March 2024, we commenced dosing in a Phase 1/2a clinical trial of envometinib for the treatment of patients with advanced solid tumors harboring RAF or RAS mutations." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000042/imrx-20251231.htm)) |
| Mar 2024 | [Immuneering Corp topline data readout](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed, positive | "In addition, in March 2024, we announced positive topline results from the Phase 1 portion of the Phase 1/2a clinical trial of IMM-1-104." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1790340/000179034024000080/imrx-20240930.htm)) |
| November 13, 2024 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/imrx-20241113xexx991.htm)) |
| March 20, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/imrx-20240229xexx9911.htm)) |
| May 5, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/imrx-20250505xexx991.htm)) |
| Jun 2025 | [Atebimetinib interim data readout](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | completed, positive | "In June 2025, we announced positive interim data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with modified Gemcitabine/nab-Paclitaxel ("mGnP") in first-line pancreatic cancer patients (the "mGnP Arm")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000104/imrx-20250630.htm)) |
| August 13, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813xexx991.htm)) |
| November 12, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/imrx-20251112xexx991.htm)) |
| Jan 2026 | [Atebimetinib interim data readout](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | completed, positive | "In January 2026, we announced further updated positive interim data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000042/imrx-20251231.htm)) |
| 2026 | [Atebimetinib trial start](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | scheduled | "Also on June 17, 2025, the Company announced that additional data from the Phase 2a portion of the Company's atebimetinib Phase 1/2a trial was expected in the fourth quarter of 2025, and that the Company planned, pending regulatory feedback expected in the fourth quarter of 2025, to initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026, and to initiate additional clinical trial combination arms evaluating atebimetinib also in 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/imrx-20250617.htm)) |
| March 6, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/imrx-20260306xexx991.htm)) |
| May 15, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/imrx-20260505xexx991.htm)) |
| August 5, 2026 | [Atebimetinib trial start](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | completed | "In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm)) |
| August 5, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm)) |
| October 29, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm)) |
| 1H 2027 | [Atebimetinib topline data readout](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | scheduled | "We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm)) |
| late 2027 | [Atebimetinib interim data readout](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | scheduled | "•In the second half of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm)) |
| late 2027 | [Libtayo® (cemiplimab) interim data readout](https://sec-api.dev/pdufa/cemiplimab) | IMRX |  | scheduled | "•4Q 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer, with a preliminary data readout expected in late-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm)) |
| mid-2028 | [Immuneering Corp topline data readout](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | scheduled | "We expect to maintain the trial's topline data readout currently planned for mid-2028, with the potential to accelerate the timing of the readout." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000097/imrx-20260930.htm)) |
| June 2028 | [Atebimetinib primary completion](https://sec-api.dev/pdufa/atebimetinib) | IMRX | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC | scheduled | "NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immuneering Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562152)) |
| Jun to Sep 2028 | [Atebimetinib topline data readout](https://sec-api.dev/pdufa/atebimetinib) | IMRX | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC | scheduled | "NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immuneering Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562152)) |

## Drugs

- [Atebimetinib](https://sec-api.dev/pdufa/atebimetinib): with advanced or metastatic solid tumors, Pancreatic Cancer
- [Envometinib](https://sec-api.dev/pdufa/envometinib): with advanced solid tumors harboring raf or ras mutations

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMRX catalysts: Immuneering Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imrx/catalysts

```bibtex
@misc{secapidev_companies_imrx_catalysts_20261116,
  title        = {IMRX catalysts: Immuneering Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imrx_catalysts_20261116","title":"IMRX catalysts: Immuneering Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
